MX2021008147A - Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos. - Google Patents
Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.Info
- Publication number
- MX2021008147A MX2021008147A MX2021008147A MX2021008147A MX2021008147A MX 2021008147 A MX2021008147 A MX 2021008147A MX 2021008147 A MX2021008147 A MX 2021008147A MX 2021008147 A MX2021008147 A MX 2021008147A MX 2021008147 A MX2021008147 A MX 2021008147A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- modified
- agonize
- polypeptide
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La presente invención provee polipéptidos que comprenden una IL-2 modificada, en donde la IL-2 modificada tiene una afinidad reducida por el receptor de IL-2R con respecto a la IL-2 de tipo salvaje; en algunas formas de realización, se proveen polipéptidos que comprenden una IL-2 modificada que se unen y agonizan las células T activadas; asimismo se proveen usos de los polipéptidos que comprenden una IL-2 modificada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962789075P | 2019-01-07 | 2019-01-07 | |
PCT/US2020/012296 WO2020146221A1 (en) | 2019-01-07 | 2020-01-06 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008147A true MX2021008147A (es) | 2021-08-11 |
Family
ID=69374426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008147A MX2021008147A (es) | 2019-01-07 | 2020-01-06 | Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220089667A1 (es) |
EP (1) | EP3908596A1 (es) |
JP (1) | JP2022516557A (es) |
KR (1) | KR20210113265A (es) |
CN (1) | CN113924311A (es) |
AR (1) | AR117770A1 (es) |
AU (1) | AU2020206672A1 (es) |
BR (1) | BR112021012294A2 (es) |
CA (1) | CA3125529A1 (es) |
CL (1) | CL2021001779A1 (es) |
IL (1) | IL284633A (es) |
MX (1) | MX2021008147A (es) |
SG (1) | SG11202106700WA (es) |
TW (1) | TW202043259A (es) |
WO (1) | WO2020146221A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ761430A (en) | 2017-08-03 | 2024-03-22 | Synthorx Inc | Cytokine conjugates for the treatment of proliferative and infectious diseases |
CN115710576A (zh) | 2018-02-01 | 2023-02-24 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
KR102313505B1 (ko) * | 2020-06-30 | 2021-10-18 | (주)지아이이노베이션 | 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
WO2022006380A2 (en) * | 2020-07-02 | 2022-01-06 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
WO2022212614A1 (en) * | 2021-03-31 | 2022-10-06 | Anwita Biosciences, Inc. | Fusion proteins, pharmaceutical compositions, and therapeutic applications |
WO2023004304A1 (en) * | 2021-07-20 | 2023-01-26 | Inhibrx, Inc. | Cd8-binding polypeptides and uses thereof |
TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
TW202328171A (zh) * | 2021-08-30 | 2023-07-16 | 美商英伊布里克斯公司 | 靶向NKp46之經修飾之IL-2多肽及其用途 |
CA3228815A1 (en) * | 2021-08-30 | 2023-03-09 | John C. Timmer | Nkp46-binding polypeptides and uses thereof |
WO2023046156A1 (en) * | 2021-09-26 | 2023-03-30 | Wuxi Biologics (Shanghai) Co. Ltd. | Il-2 variants and fusion proteins thereof |
TW202334193A (zh) * | 2022-01-05 | 2023-09-01 | 美商英伊布里克斯公司 | 靶向γδ T細胞之經修飾IL-2多肽及其用途 |
WO2024026449A2 (en) * | 2022-07-28 | 2024-02-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 procytokine antibody fusion proteins |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
SI1678314T1 (sl) | 2003-10-22 | 2013-01-31 | Keck Graduate Institute | Metode za sintetiziranje heteromultimernih polipeptidov pri kvasovkah s strategijo razmnoĺ˝evanja haploidnih celic |
CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验*** |
JP2007527242A (ja) * | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | 治療剤の患者耐容性を予測するためのインビトロ試験システム |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
PE20140303A1 (es) * | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
MX370283B (es) * | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas. |
KR20180133198A (ko) * | 2016-05-04 | 2018-12-13 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
BR112019024127A2 (pt) * | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
-
2020
- 2020-01-06 CA CA3125529A patent/CA3125529A1/en active Pending
- 2020-01-06 JP JP2021538982A patent/JP2022516557A/ja active Pending
- 2020-01-06 WO PCT/US2020/012296 patent/WO2020146221A1/en unknown
- 2020-01-06 CN CN202080018011.6A patent/CN113924311A/zh active Pending
- 2020-01-06 TW TW109100336A patent/TW202043259A/zh unknown
- 2020-01-06 KR KR1020217024431A patent/KR20210113265A/ko unknown
- 2020-01-06 EP EP20702547.9A patent/EP3908596A1/en active Pending
- 2020-01-06 AR ARP200100028A patent/AR117770A1/es unknown
- 2020-01-06 AU AU2020206672A patent/AU2020206672A1/en active Pending
- 2020-01-06 US US17/418,458 patent/US20220089667A1/en active Pending
- 2020-01-06 MX MX2021008147A patent/MX2021008147A/es unknown
- 2020-01-06 SG SG11202106700WA patent/SG11202106700WA/en unknown
- 2020-01-06 BR BR112021012294-0A patent/BR112021012294A2/pt unknown
-
2021
- 2021-07-05 IL IL284633A patent/IL284633A/en unknown
- 2021-07-05 CL CL2021001779A patent/CL2021001779A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL284633A (en) | 2021-08-31 |
BR112021012294A2 (pt) | 2021-09-08 |
WO2020146221A1 (en) | 2020-07-16 |
JP2022516557A (ja) | 2022-02-28 |
CA3125529A1 (en) | 2020-07-16 |
US20220089667A1 (en) | 2022-03-24 |
TW202043259A (zh) | 2020-12-01 |
KR20210113265A (ko) | 2021-09-15 |
AU2020206672A1 (en) | 2021-07-15 |
SG11202106700WA (en) | 2021-07-29 |
CL2021001779A1 (es) | 2022-03-04 |
AR117770A1 (es) | 2021-08-25 |
CN113924311A (zh) | 2022-01-11 |
EP3908596A1 (en) | 2021-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021008147A (es) | Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos. | |
MX2022016532A (es) | Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos. | |
WO2020092854A3 (en) | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) | |
MX2020002596A (es) | Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos. | |
MX2017012805A (es) | Complejo de unión a antígenos con actividad agonista y métodos de uso. | |
PH12019550147A1 (en) | Engineered transferrin receptor binding polypeptides | |
GEP20237480B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
MX2011012184A (es) | Polipeptidos bifuncionales. | |
PH12019502273A1 (en) | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 | |
MA40609B1 (fr) | Agents de liaison cd123 et leurs utilisations | |
NZ756224A (en) | Polypeptide variants and uses thereof | |
MX2009008230A (es) | Epitopes de celulas t reguladoras, composiciones y usos para los mismos. | |
MX2015014017A (es) | Variante de la region fc. | |
WO2020160156A3 (en) | Anti-gal3 antibodies and uses thereof | |
MY187827A (en) | New polypeptide having affinity to pd-l1 | |
EP3787080A4 (en) | FUEL CELL CATALYST, MEMBRANE ELECTRODE ARRANGEMENT FOR FUEL CELL AND FUEL CELL WITH IT | |
AU2019321490A8 (en) | Ox40-binding polypeptides and uses thereof | |
EP3835320A4 (en) | BINDING OF CHEMERA ANTIGEN RECEPTOR TO HLA-DR, AND CAR-T CELL | |
WO2011056954A3 (en) | Haemophilus parasuis polypeptides and methods of use | |
BR112019013005A2 (pt) | espécie de metschnikowia isolada, método para produzir xilitol, xilitol bioderivado e composição | |
MX2022012541A (es) | Inmunoconjugados. | |
EP3672724A4 (en) | ELECTRIC CATALYSTS, THEIR PRODUCTION AND USE FOR FUEL CELLS | |
MX2022013840A (es) | Polipéptidos de unión a pd-1 canina y usos de los mismos. | |
WO2020235974A3 (ko) | 단일염기 치환 단백질 및 이를 포함하는 조성물 | |
EP3767723A4 (en) | ELECTRODE CATALYST FOR FUEL CELL AND FUEL CELL WITH USE THEREOF |